Y-mabs therapeutics, inc. announces closing of public offering and full exercise of the underwriters' option to purchase additional shares

New york, feb. 22, 2021 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the closing of its public offering of 2,804,878 shares of its common stock, at a public offering price of $41.00 per share, which includes the exercise in full of the underwriters' option to purchase 365,853 additional shares of common stock. the aggregate gross proceeds to y-mabs, before deducting underwriting discounts and commissions and estimated offering expenses payable by the company, were approximately $115 million. all of the shares of common stock were offered by the company. y-mabs' common stock is listed on the nasdaq global select market under the ticker symbol "ymab."
YMAB Ratings Summary
YMAB Quant Ranking